Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Kamada will "imminently" begin a U.S. Phase II/III trial of IV Glassia as an add-on to steroid treatment in about 168 GvHD patients with lower gastrointestinal involvement. An open-label portion will ...
BCIQ Company Profiles
Kamada Ltd.
Shire plc
BCIQ Target Profiles
A1AT
AAT
Alpha-1 antitrypsin (AAT) (A1AT) (SERPINA1)
Elastase